Citius Oncology, Inc. (CTOR) Institutional Ownership

Ownership Summary

The institutional landscape for Citius Oncology, Inc. (NASDAQ:CTOR) includes 15 filers as of the latest reporting cycle ending September 2025.

• The percentage of Citius Oncology owned by institutions changed from 0.3% in June 2025 to 11.3% in September 2025, marking a slight up trend.
• On a quarter-over-quarter basis, institutional holdings shifted by 6728.86%, with a year-over-year an increase of 66.67% in the count of filers.
• A review of institutional activity for Citius Oncology shows 12 of 15 filers increasing their positions, while 2 reduced their stake, and 1 remained unchanged.
• The aggregate institutional position in Citius Oncology now stands at 8.23Mn shares as of September 2025, after investors increased their holdings (up by 8.11Mn shares quarter on quarter which is up 8.17Mn shares year over year).
• With 7.68Mn shares, ARMISTICE CAPITAL, LLC commands the largest institutional position in Citius Oncology as of September 30, 2025, equating to 10.54% of the company.
• Among the most significant buyers of Citius Oncology during September 2025 were ARMISTICE CAPITAL, LLC (7.68Mn), VANGUARD GROUP INC (180.17K), GEODE CAPITAL MANAGEMENT, LLC (109.88K), RENAISSANCE TECHNOLOGIES LLC (55.90K), STATE STREET CORP (42.90K).
• Leading sellers of Citius Oncology stock in September 2025 included UBS Group AG (15.37K), BANK OF AMERICA CORP /DE/ (8.31K).
• The top 10 institutional holders of Citius Oncology for the quarter ending September 2025 included ARMISTICE CAPITAL, LLC (7.68Mn), VANGUARD GROUP INC (180.17K), GEODE CAPITAL MANAGEMENT, LLC (167.17K), RENAISSANCE TECHNOLOGIES LLC (55.90K), STATE STREET CORP (42.90K), IFP Advisors, Inc (33.22K), NORTHERN TRUST CORP (21.76K), CITADEL ADVISORS LLC (17.66K), Tower Research Capital LLC (TRC) (11.85K), OSAIC HOLDINGS, INC. (11.74K).